HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

TNFR-Fc fusion protein (etanercept)

Subscribe to New Research on TNFR-Fc fusion protein

reduces tumor necrosis factor activity, as well as cytokine, chemokine, and stress hormone release; used to treat SPONDYLITIS, ANKYLOSING

Also Known As:

etanercept; Enbrel; Immunex brand of etanercept; TNF receptor type II-IgG fusion protein; TNR 001; TNR-001; TNT receptor fusion protein; TNTR-Fc; Wyeth brand of etanercept; recombinant human dimeric TNF receptor type II-IgG fusion protein

Networked: 3122 relevant articles (575 outcomes, 664 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Gottlieb, Alice B: 25 articles (08/2015 - 11/2003)
2.	Chimenti, Sergio: 20 articles (08/2015 - 01/2006)
3.	Freundlich, Bruce: 20 articles (02/2015 - 04/2007)
4.	Davis, John C: 19 articles (05/2015 - 05/2002)
5.	Dougados, Maxime: 19 articles (08/2014 - 07/2003)
6.	Moreland, Larry W: 19 articles (08/2013 - 06/2002)
7.	Koenig, Andrew S: 18 articles (02/2015 - 08/2008)
8.	Emery, Paul: 18 articles (01/2015 - 01/2004)
9.	Combe, Bernard: 18 articles (01/2015 - 07/2003)
10.	Curtis, Jeffrey R: 17 articles (01/2016 - 09/2010)

Related Diseases

1.	Psoriasis (Pustulosis Palmaris et Plantaris) 02/01/2009 - "To assess the cost-effectiveness of etanercept 50 mg biw for the treatment of chronic plaque psoriasis, and to explore characteristics of patients who benefited most from 50 mg dosing. " 09/01/2011 - "Marked improvement in nail psoriasis during treatment with etanercept." 08/01/2010 - "In two previous phase 3 studies, up to 60 weeks of etanercept therapy significantly improved the symptoms of psoriasis and was well tolerated. " 06/01/2005 - "In previous studies, etanercept significantly improved plaque psoriasis and was well tolerated. " 05/01/2010 - "In conclusion, etanercept provided significant, sustained improvement in disease severity and was well tolerated in children > or = 8 years with severe plaque psoriasis."
2.	Rheumatoid Arthritis 01/01/2003 - "Overall, etanercept is highly effective and well tolerated by patients with PsA, with a safety profile similar to that seen in rheumatoid arthritis." 01/01/2011 - "Two cases of women with rheumatoid arthritis in complete remission of the disease with etanercept who decided to continue the therapy throughout their pregnancy are presented. " 01/01/2008 - "Efficacy of etanercept and complete decongestive physical therapy in bilateral lower-limb lymphoedema associated with rheumatoid arthritis: a case report." 01/01/2014 - "High rate of disease remission in moderate rheumatoid arthritis on etanercept therapy: data from GISEA, the Italian biologics register." 12/01/2005 - "Etanercept, approved in the United States and in Europe for use in patients with rheumatoid arthritis (RA) and JRA, is an effective inhibitor of TNF that has been shown to provide rapid and sustained improvement in both diseases. "
3.	Ankylosing Spondylitis 12/01/2011 - "Etanercept 50 mg weekly treatment of Chinese patients with active ankylosing spondylitis is convenient, fast-acting, highly effective, and well tolerated." 01/01/2004 - "In randomized, double-blind, placebo-controlled trials, subcutaneous etanercept 25mg twice weekly for 6-24 weeks significantly reduced disease activity in patients with active ankylosing spondylitis. " 04/01/2008 - "Rapid and sustained improvement in health-related quality of life and utility for 72 weeks in patients with ankylosing spondylitis receiving etanercept." 12/01/2006 - "Patients with ankylosing spondylitis can expect a comparable significant improvement in clinical outcomes with similar safety when treated with etanercept 50 mg once weekly or with 25 mg twice weekly." 01/01/2004 - "Etanercept therapy significantly improved health-related quality of life in patients with ankylosing spondylitis compared with placebo. "
4.	Psoriatic Arthritis 01/01/2003 - "In the 24-week study, ACR20 response rates (50 vs 13%), psoriatic arthritis response rates (70 vs 23%) and the median improvement in skin lesions (33 vs 0%) were significantly greater in etanercept than in placebo recipients. " 01/01/2003 - "In patients with psoriatic arthritis, etanercept 25mg twice weekly significantly reduced disease activity and improved skin lesions in two double-blind, placebo-controlled, 12- to 24-week trials. " 01/01/2002 - "In the 24-week study, ACR20 response rates (50 vs 13%), psoriatic arthritis response rates (70 vs 23%) and the median improvement in skin lesions (33 vs 0%) were significantly greater in etanercept than in placebo recipients. " 01/01/2002 - "In patients with psoriatic arthritis, etanercept 25mg twice weekly significantly reduced disease activity and improved skin lesions in two double-blind, placebo-controlled, 12- to 24-week trials. " 11/01/2000 - "In patients with severe psoriatic arthritis (PsA), a double blind, placebo controlled study demonstrated that etanercept was also effective in reducing disease activity in PsA. "
5.	Juvenile Rheumatoid Arthritis (Juvenile Idiopathic Arthritis) 01/01/2011 - "Complete control of disease activity and remission induced by treatment with etanercept in juvenile idiopathic arthritis." 08/01/2009 - "Treatment with etanercept once weekly using a double dosage leads to a significant improvement of disease activity in patients with active polyarticular course juvenile idiopathic arthritis and is well tolerated." 01/01/2003 - "In patients with polyarticular-course juvenile rheumatoid arthritis, etanercept resulted in improvements in all measures of disease activity and was significantly more effective than placebo at reducing disease flare. " 01/01/2002 - "In patients with polyarticular-course juvenile rheumatoid arthritis, etanercept resulted in improvements in all measures of disease activity and was significantly more effective than placebo at reducing disease flare. " 07/01/2001 - "Safety and efficacy of high dose etanercept in treatment of juvenile rheumatoid arthritis."

Related Drugs and Biologics

1.	infliximab (Remicade)
2.	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
3.	adalimumab (Humira)
4.	Methotrexate (Mexate)
5.	TNFR-Fc fusion protein (etanercept)
6.	Tumor Necrosis Factor Receptors (Tumor Necrosis Factor Receptor)
7.	monoclonal antibody CNTO 1275 (CNTO 1275)
8.	Antirheumatic Agents (DMARD)
9.	efalizumab
10.	golimumab

Related Therapies and Procedures

1.	Phototherapy (Light Therapy)
2.	Aftercare (After-Treatment)
3.	Biological Therapy
4.	Remission Induction
5.	Laminectomy